| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
During the last three months, 4 analysts shared their evaluations of Ardelyx (NASDAQ:ARDX), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Ardelyx and provided 12-month price targets. The average target is $11.25, accompanied by a high estimate of $14.00 and a low estimate of $9.00. Witnessing a positive shift, the current average has risen by 5.44% from the previous average price target of $10.67.
The standing of Ardelyx among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Christopher Raymond | Piper Sandler | Raises | Neutral | $9.00 | $8.00 |
| Laura Chico | Wedbush | Raises | Outperform | $14.00 | $13.00 |
| Ryan Deschner | Raymond James | Raises | Outperform | $12.00 | $11.00 |
| Matthew Caufield | HC Wainwright & Co. | Announces | Buy | $10.00 | - |
Capture valuable insights into Ardelyx's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Ardelyx analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Ardelyx's revenue growth over a period of 3M has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 33.38%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -19.54%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ardelyx's ROE excels beyond industry benchmarks, reaching -13.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Ardelyx's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.35% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Ardelyx's debt-to-equity ratio surpasses industry norms, standing at 1.48. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ARDX
